Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2145 - 2152 of 11617 results
Entrepreneurs of Color Receive Strategic Guidance
February 22, 2022| Article| Viewpoint
Minimizing Stockholder Litigation Risks
February 18, 2022| Blog| Viewpoint
DOJ Tells Cybercriminals, “If you continue to come for us we will come for you” and Warns Companies to Keep Their “Cyber Shields Up”
February 18, 2022| Blog| Viewpoint
(Updated) Congress Ends Mandatory Arbitration of Sexual Harassment and Sexual Assault Claims
February 18, 2022| Blog| Viewpoint
Facebook to Pay $90 Million to Settle Data Privacy Lawsuit
February 18, 2022| Blog| Viewpoint
EXCLUSIVE RIGHTS: Intellectual Property — Domestic Industry at the ITC – The Commission Has Set a Positive Trend
February 18, 2022| Podcast| Viewpoint
D. Del. Says ANDA Specification Trumps All Else in Infringement Analysis
February 17, 2022| Blog| Viewpoint
CBP Begins Issuing New I-94 Designations for L-2 and E Dependent Spouses Granting Employment Authorization Incident to Status
February 17, 2022| Alert| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.